Biocon unveils biologic drug to treat skin disorder

Our Bureau Bangalore | Updated on March 12, 2018 Published on August 10, 2013

Kiran Mazumdar-Shaw, Chairperson and MD, Biocon, at the launch of ALZUMAb injection in Bangalore

Kiran Mazumdar Shaw (L), Chairperson and MD, Rakesh Bamzai, President, Marketing, and Shukrit Sudhir Chimote, Head, Branded Formulations, India, all Biocon, at the launch of Alzumab injection in Bangalore on Saturday. - Photo: G R N Somashekar

Bangalore-based biotechnology company Biocon has launched a new biologic that could treat patients with psoriasis.

A biologic is a preparation, such as a drug, a vaccine, or an anti-toxin, which is synthesized from living organisms or their products and used to diagnose, prevent or treat patients.

Called ALZUMAb, it can treat psoriasis, a skin disorder with better efficiency and a low infection rate and will retail at Rs 7,500 for a bottle, according to company officials.

Further, this biologic has a longer remission period, which helps a patient to reduce medication costs as they have to repeatedly buy this product due to the relapsing nature of the disease.

“This new line of treatment will usher in a paradigm shift in the management of psoriasis. We are proud that this will be the first instance of a breakthrough innovation from India with a potential to treat multiple autoimmune diseases,” said Kiran Mazumdar-Shaw, Chairperson and Managing Director.

In January, Biocon received marketing authorisation from the Drugs Controller General of India (DCGI) for its novel biologic ‘Itolizumab’ – anti-CD6 molecule.

With this launch, Biocon has one eye on the $8-billion psoriasis market which, according to analysts is estimated to hit that size by 2016.

With the pricing of ALZUMAb almost 50 per cent cheaper than other psoriasis drugs, Biocon hopes to gain more market share but did not put a number to it.

Published on August 10, 2013
This article is closed for comments.
Please Email the Editor